IMVT at a glance
Immunovant, Inc. (IMVT, SEC CIK 1764013) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Immunovant, Inc. (IMVT) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Pande Atul on November 11, 2026 of 3,000 shares at $36.00 per share.
- In the last 90 days, IMVT insiders reported 0 open-market purchases ($0) and 10 open-market sales ($896K) on Form 4, a net sale of $896K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$896K
- 13F holders
- 27 funds
- $1.2B · −2 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, reflecting no commercialized products
- Net loss $97.2M vs $126.5M YoY, operating expenses $104.2M vs $131.8M
- Best R&D area, endocrine $22.5M; worst, neurological $18.3M, both down YoY
- Cash $722.3M vs $902.1M at March 31; operating cash used $207.6M
- Cash expected to fund operations through potential GD launch; expanded development could shorten runway
Risk Factors
- No material risk-factor changes during quarter ended September 30, 2026
- Carried-forward risks include potential adverse effects on business, operations, financial condition and cash flows
- Share-price risk: adverse events could reduce Immunovant common-stock value
- Investment risk: shareholders could lose all or part of their investment
AI summary of the IMVT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q2 and six months ended September 30, 2026 financial results announced
- Press release dated November 9, 2026 contains the results and accompanying management disclosures
Item EX-99.1: Item EX-99.1
- IMVT-1402 600 mg met primary ACR20 endpoint in D2T RA: 92.5% vs 75.6% placebo, p=0.0139
- Dose differentiation emerged: 300 mg showed no placebo advantage, with 75.0% ACR20 response, p=0.9426
Item 5.07: Submission of Matters to a Vote of Security Holders
- 198,373,370 shares represented, approximately 96% of eligible voting shares, indicating strong shareholder participation
- Bauer, Hughes, and Susman re-elected to the Board through the 2027 annual meeting
Item EX-99.1: Item EX-99.1
- IMVT-1402 timelines remain on track across six autoimmune indications, with GD and MG topline data expected in 2027
- Cash $797.8M supports potential IMVT-1402 launch in GD, but quarterly cash declined from $902.1M at March 31, 2026
Item 2.02: Results of Operations and Financial Condition
- Fiscal first-quarter results for the period ended June 30, 2026
- Press release provides Immunovant’s financial results and management commentary as Exhibit 99.1
AI summaries of IMVT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IMVT
Don't miss the next IMVT filing
- Alerts as it files. A push when IMVT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IMVT, by share count.
- Ask anything. An AI agent that reads every IMVT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Pande Atul | Sell | Nov 11, 2026 | 3,000 | $36.00 |
| Pande Atul | M | Nov 11, 2026 | 3,000 | - |
| Pande Atul | M | Nov 11, 2026 | 3,000 | $8.43 |
| Girao Tiago | Sell | Oct 28, 2026 | 6,606 | $28.50 |
| Stout Jay S | Sell | Oct 21, 2026 | 2,595 | $28.94 |
| Stout Jay S | Sell | Oct 7, 2026 | 2,213 | $32.06 |
| Stout Jay S | Sell | Oct 7, 2026 | 1,596 | $32.06 |
| Van Tuyl Christopher | Sell | Oct 7, 2026 | 1,327 | $32.06 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|
| Profitability | ||||
| Net Income | -$259.3M | -$413.8M | -$505.6M | |
| Balance Sheet | ||||
| Total Assets | $666.4M | $776.2M | $957.0M | |
| Equity | $617.8M | $707.4M | $852.6M | |
| ROE | -42.0% | -58.5% | -59.3% | |
| Per Share | ||||
| EPS | $-1.88 | $-2.73 | $-2.77 | |
| Cash Flow | ||||
| Operating CF | -$214.2M | -$375.9M | -$407.3M | |
| CapEx | $360K | $759K | $8K | |
Source: XBRL data in Immunovant, Inc. (IMVT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate IMVT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $1.16B |
| Q2 2026 | 29 | $1.89B |
| Q1 2026 | 25 | $1.09B |
| Q4 2025 | 20 | $1.11B |
| Q3 2025 | 20 | $595.0M |
| Q2 2025 | 23 | $660.1M |
| Q1 2025 | 22 | $600.7M |
| Q4 2024 | 20 | $704.0M |
- Morgan Stanley+1.15M (+25%)
- Vanguard Capital Management LLC+448.6K (+12%)
- BNY Mellon+359.7K (+122%)
- Vanguard Portfolio Management LLC+354.2K (+9%)
- BlackRock+244.9K (+3%)
- State Street Corp−420.6K (-9%)
- Goldman Sachs Group−149.0K (-9%)
- D.E. Shaw & Co−132.9K (-11%)
- Millennium Management−71.9K (-22%)
- Citigroup−66.9K (-58%)
- Two Sigma Investments+27.8K
- FMR LLC (Fidelity)−16.19M
- Citadel Advisors LLC−160.1K
- Raymond James Financial−5.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IMVT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
IMVT SEC filings: frequently asked questions
Are IMVT insiders buying or selling?
In the last 90 days, Immunovant, Inc. (IMVT) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $895,852 by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold IMVT stock?
As of September 30, 2026, the largest Immunovant, Inc. (IMVT) holders among the 13F filers tracked by SignalX were BlackRock ($250.8 million), Morgan Stanley ($192.0 million), Vanguard Portfolio Management LLC ($144.1 million), State Street Corp ($141.8 million), Vanguard Capital Management LLC ($138.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did IMVT report in its latest 8-K?
Immunovant, Inc. (IMVT) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal Q2 and six months ended September 30, 2026 financial results announced.
What are the latest IMVT SEC filings?
Immunovant, Inc. (IMVT) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.
What is IMVT's SEC CIK number?
Immunovant, Inc. (IMVT)'s SEC Central Index Key (CIK) is 1764013. EDGAR lists every IMVT filing under that number.
Ask anything about IMVT
The research agent reads IMVT's filings, financials, insider trades and 13F holders, then answers with sources.